search

Active clinical trials for "Hepatomegaly"

Results 1-10 of 10

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders...

BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White Cells11 more

This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.

Recruiting43 enrollment criteria

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

AmorphousEosinophilic13 more

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

Active40 enrollment criteria

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis,...

HepatomegalyMyelofibrosis Transformation in Essential Thrombocythemia4 more

This phase II trial studies how well nivolumab works in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Terminated20 enrollment criteria

Lanreotide as Treatment of Polycystic Livers

Polycystic Liver DiseaseHepatomegaly3 more

To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.

Completed12 enrollment criteria

Octreotide in Severe Polycystic Liver Disease

Polycystic KidneyAutosomal Dominant6 more

This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection or liver transplantation. A total of 42 patients will be recruited -14 who will receive placebo and 28 the study drug. Preliminary evidence indicates that this drug is safe and non-toxic in other disease states. Treatment with this drug holds promise not only for individuals with liver involvement, but also for many more patients with polycystic kidney disease.

Completed14 enrollment criteria

Open-Label Extension of LOCKCYST Trial

Polycystic Liver DiseaseHepatomegaly3 more

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available. Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

Unknown status13 enrollment criteria

Biomarker for Gaucher Disease: BioGaucher (BioGaucher)

SplenomegalyHepatomegaly

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Gaucher Disease from blood (plasma)

Withdrawn11 enrollment criteria

Biomarker for Sly Disease (MPS VII) (BioSly)

Developmental DelaySkeletal Abnormalities2 more

Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)

Withdrawn12 enrollment criteria

Biomarker for Farber Disease (BioFarber)

Farber's LipogranulomatosisCeramidase Deficiency2 more

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood

Withdrawn17 enrollment criteria

Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus

Hepatomegaly

To assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.

Unknown status3 enrollment criteria
1

Need Help? Contact our team!


We'll reach out to this number within 24 hrs